Review
Open access
Sep 2026
Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications
A pattern emerges, where FXI/FXIa inhibition offers a favorable safety profile across multiple settings and high-risk subgroups, yet clear efficacy has so far been established only in secondary prevention of noncardioembolic ischemic stroke over existing antiplatelet strategies.
Ermioni Oikonomou, Mark Goldin, A. Spyropoulos
· Journal of Clinical Medicine · 0 citations